Evidence map›Paper›PMID 22252093›Full record

ArticleJournal of thrombosis and haemostasis : JTH2012

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.

T I Verhoef, W K Redekop, M M Buikema, T Schalekamp, F J M Van Der Meer, S Le Cessie, J A M Wessels, R M F Van Schie, A De Boer, M Teichert and 3 more

3 registry-linked trialsAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
8.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01119261 phase4completednot on this map

EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol

TypeinterventionalSponsorUtrecht Institute for Pharmaceutical SciencesRan2010 to 2013Enrolled970ConditionsVenous Thromboembolism, Atrial FibrillationArmsGenotype-guided dosing algorithm, Non-genotype-guided dosing algorithm
NCT01119274 phase4completednot on this map

EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon

TypeinterventionalSponsorUtrecht Institute for Pharmaceutical SciencesRan2010 to 2013Enrolled970ConditionsVenous Thromboembolism (VTE), Atrial Fibrillation (AF)ArmsGenotype-guided dosing algorithm, Non-genotype-guided dosing algorithm
NCT01119300 phase4completednot on this map

EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin

TypeinterventionalSponsorUtrecht Institute for Pharmaceutical SciencesRan2011 to 2013Enrolled455ConditionsVenous Thromboembolism, Atrial FibrillationArmsGenotype-guided dosing algorithm, Standard care
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Applications of CYP450 testing in the clinical setting.Molecular diagnosis & therapy · 2013
    Review
  7. Personalized medicine: is it a pharmacogenetic mirage?British journal of clinical pharmacology · 2012
    Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

T I VerhoefDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciuences, Utrecht University, Utrecht, the Netherlands.
W K Redekop
M M Buikema
T Schalekamp
F J M Van Der Meer
S Le Cessie
J A M Wessels
R M F Van Schie
A De Boer
M Teichert
L E Visser
A H Maitland-Van Der Zee
EU-PACT Group
Pharmo Institute · NLUtrecht University · NLErasmus MC · NLInstitute of Technology Assessment · ATLeiden University Medical Center · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes. However, the duration of the effects of these genes on anticoagulation is not yet known.

objectivesIn the present study, the effects of these polymorphisms on the risk of underanticoagulation and overanticoagulation over time after the start of acenocoumarol were investigated. PATIENTS/

methodsIn three cohorts, we analyzed the relationship between the CYP2C9 and VKORC1 genotypes and the incidence of subtherapeutic or supratherapeutic International Normalized Ratio (INR) values (< 2 and > 3.5) or severe overanticoagulation (INR > 6) for different time periods after treatment initiation.

resultsPatients with polymorphisms in CYP2C9 and VKORC1 had a higher risk of overanticoagulation (up to 74%) and a lower risk of underanticoagulation (down to 45%) in the first month of treatment with acenocoumarol, but this effect diminished after 1-6 months.

conclusionsKnowledge of the patient's genotype therefore might assist physicians to adjust doses in the first month(s) of therapy.

Indexed as

AcenocoumarolAgedAnticoagulantsAryl Hydrocarbon HydroxylasesBlood CoagulationCytochrome P-450 CYP2C9Drug Administration ScheduleDrug Dosage CalculationsDrug MonitoringFemaleGene FrequencyGenotypeHumansInternational Normalized RatioMaleMedication ErrorsAcenocoumarolAnticoagulantsAryl Hydrocarbon HydroxylasesCYP2C9 protein, humanCytochrome P-450 CYP2C9Mixed Function OxygenasesVitamin K Epoxide ReductasesVKORC1 protein, human

Identifiers

PMID22252093
OpenAlexW1528722311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.